Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression.

Area of Science:

• Molecular Biology
• Cancer Biology
• Biochemistry

Background:

• TNF receptor associated factor 6 (TRAF6) is an E3 ubiquitin ligase linked to myeloid malignancies.
• Its specific role in acute myeloid leukemia (AML) pathogenesis is not well understood.

Purpose of the Study:

• To investigate the function of TRAF6 in AML pathogenesis.
• To explore the metabolic consequences of TRAF6 loss in AML cells.
• To identify novel regulatory pathways involving TRAF6 in leukemia.

Main Methods:

• Investigated the effects of TRAF6 loss on AML cell function in vitro and in vivo.
• Analyzed metabolic alterations including glycolysis, TCA cycle, nucleic acid metabolism, and mitochondrial function.
• Examined the correlation between TRAF6 and O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) expression.
• Assessed the impact of OGT restoration and O-GlcNAcase (OGA) inhibition on TRAF6-deficient AML cells.

Main Results:

• Loss of TRAF6 significantly impairs AML cell function both in vitro and in vivo.
• TRAF6 deficiency leads to profound metabolic alterations, including impaired glycolysis, TCA cycle, nucleic acid metabolism, and mitochondrial function.
• TRAF6 expression positively correlates with OGT expression in leukemic cells.
• Restoring OGT or inhibiting OGA rescues the growth and metabolic activity of TRAF6-deficient AML cells.

Conclusions:

• TRAF6 plays an oncogenic role in leukemia.
• The TRAF6/OGT/O-GlcNAc axis is a novel regulator of metabolic reprogramming in leukemogenesis.
• Targeting this axis may offer new therapeutic strategies for AML.